Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Noura J. Choudhury"'
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Jessica J. Lin, Yunan Nie, Alexia Iasonos, Andrew J. Plodkowski, Maria E. Arcila, Debra A. Goldman, Jaime L. Schneider, Viola W. Zhu, Sai-Hong Ignatius Ou, Natasha Rekhtman, Alexander Drilon, Subba R. Digumarthy, Tejas Patil, Jamie E. Chaft, Christina Falcon, Andrew Do, Noura J. Choudhury, Soo-Ryum Yang
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100187-(2021)
Introduction: ROS1 fusions are oncogenic drivers in 1% to 3% of NSCLCs. The activity of immune checkpoint inhibitor (ICI) monotherapy or in combination with chemotherapy (chemotherapy with ICI [chemo-ICI]) in these tumors and their immunophenotype ha
Autor:
Maria E. Arcila, Charles M. Rudin, Glenn Heller, Adam J. Schoenfeld, Gregory J. Riely, Marc Ladanyi, Jessica Flynn, Hira Rizvi, Mark G. Kris, Helena A. Yu, Noura J. Choudhury, Christina Falcon
Publikováno v:
Clin Cancer Res
Purpose: EGFR exon 20 insertions (ex20ins) are an uncommon genotype in non–small cell lung cancer (NSCLC) for which targeted therapies are under development. We sought to describe treatment outcomes and genomic and immunophenotypic characteristics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96ab74d61f0f759a9ab027ae10ff52f8
https://europepmc.org/articles/PMC8127357/
https://europepmc.org/articles/PMC8127357/
Autor:
Abraham J. Wu, V. Rusch, Andreas Rimner, Bernard J. Park, Harper Hubbeling, E. Ziv, Charles B. Simone, Daniel R. Gomez, Christina Falcon, Annemarie F. Shepherd, A. Drilon, Daphna Y. Gelblum, Narek Shaverdian, Noura J. Choudhury
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e438-e439
Purpose/Objective(s) Local therapy (LTX) prolongs progression-free and overall survival (OS) in patients with oligometastatic non-small cell lung cancer. We previously reported substantial LTX benefit in time to progression or next therapy (TTP/TTNT)